Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $23.8 million.

  • Day One Biopharmaceuticals' Non-Current Assets rose 2018.07% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.6 million, marking a year-over-year increase of 14582.46%. This contributed to the annual value of $20.5 million for FY2024, which is 254315.25% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Non-Current Assets stood at $23.8 million, which was up 2018.07% from $24.6 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Non-Current Assets registered a high of $25.7 million during Q1 2025, and its lowest value of $611000.0 during Q1 2024.
  • For the 4-year period, Day One Biopharmaceuticals' Non-Current Assets averaged around $12.4 million, with its median value being $17.3 million (2024).
  • In the last 5 years, Day One Biopharmaceuticals' Non-Current Assets plummeted by 3484.85% in 2023 and then surged by 410703.76% in 2025.
  • Over the past 4 years, Day One Biopharmaceuticals' Non-Current Assets (Quarter) stood at $1.2 million in 2022, then plummeted by 34.85% to $774000.0 in 2023, then skyrocketed by 2543.15% to $20.5 million in 2024, then rose by 16.38% to $23.8 million in 2025.
  • Its last three reported values are $23.8 million in Q3 2025, $24.6 million for Q2 2025, and $25.7 million during Q1 2025.